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Acute lymphoblastic leukemia (ALL) is the most com-
mon type of cancer encountered in pediatric medicine,
accounting for 30% of all childhood malignancies [1].
Chemotherapy is the mainstay of treatment and risk-
adapted therapy has been developed to improve the
event-free survival rate, as well as to reduce therapy-
related complications. Important prognostic factors
include age at the time of diagnosis and initial white
blood cell (WBC) count. Cytogenetic and molecular
genetic abnormalities are also important factors [2],
while chromosomal karyotype and translocation in
cytogenetic studies both have considerable prognostic
value [3–5].
Since the discovery of the first fusion gene, BCR-
ABL, resulting from a t(9;22) translocation, many fusion
transcripts that occur in leukemia, such as t(12;21),
t(4;11), and t(1;19), have subsequently been detected [6].
Research has shown that normally-fused translocated
genes play a crucial role in the development and func-
tion of lymphocytes and bone marrow cells [7]. It has
therefore been suggested that the fusion genes may be
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Chromosomal abnormalities are found in 80–90% of childhood cases of acute lymphoblastic
leukemia (ALL). Leukemia-specific chromosome aberrations not only have prognostic value, but also
provide important clues for further investigation into leukogenesis, leukemic cell transformation,
and proliferation. This study used reverse transcriptase–polymerase chain reaction techniques to
detect transcripts of the leukemia-specific chromosome fusion gene, TEL/AML1, and to monitor
the expression levels of the TEL-AML1 fusion transcript in ALL patients at sequential intervals
during their treatment course. Twenty-five ALL patients were enrolled, including 20 who were
newly diagnosed and five in relapse. The incidence of the TEL/AML1 fusion gene in this study
was 32%. The clinical features of our eight TEL/AML1-positive ALL cases were similar to those
in other studies. Blotting analysis of the levels of the TEL-AML1 fusion transcript was used to
detect minimal residual disease. Reduced levels of TEL/AML1 expression were found in four of
the six patients whose bone marrow or peripheral blood samples were obtained after treatment.
Further investigation with a larger sample size is warranted.
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closely correlated with the onset of leukemia. Advances
in molecular genetics have demonstrated that many
fusion genes are difficult to detect with conventional
karyotyping and highlight the value of molecular
genetics in the diagnosis and treatment of leukemia.
The TEL gene, also known as the ETV6 gene, was
first identified in chronic myelomonocytic leukemia
as part of a fusion with the PDGFRβ receptor gene
[8]. Subsequently, many cases of ALL with TEL gene
rearrangement have been reported and a partner
gene was found to be the AML gene located on chro-
mosome 21 [9]. Such a fusion gene has been found in
approximately 20–25% of ALL cases in children, but
less than 0.05% of these can be detected with conven-
tional cytogenetic studies. Most patients are between
the ages of 1 and 10 years, white cell count <50,000/μL,
with a B immunophenotype [9–11].
Studies by the Dana Farber Cancer Institute and
St Jude’s Children Hospital demonstrated that patients
with the TEL/AML1 fusion gene had an excellent prog-
nosis (100% 8-year event-free survival and 92% 5-year
event-free survival, respectively) [12,13]. However,
the British-Frankfurt-Muenster leukemia group later
identified the TEL/AML1 fusion gene in 25% of ALL
patients who relapsed [14–16], and that better prog-
nostic outcome was probably associated with stronger
chemotherapy regimens in the past [17]. Thus, the
correlation between the TEL/AML1 fusion gene and
disease prognosis requires further investigation.
This study recruited both newly diagnosed and
relapsed ALL children. By employing reverse 
transcriptase–polymerase chain reaction (RT-PCR), the
translocation t(12;21) producing the TEL/AML1 fusion
gene was detected. Their correlations with the local
incidence of disease and other prognostic factors (in-
cluding age, white cell count, and immunophenotype
of disease) were explored and analyzed. Furthermore,
the TEL/AML1 fusion gene was used as a marker of
the relative changes in residual illness during the
course of therapy.
MATERIALS AND METHODS
Patients and samples
We recruited 25 ALL patients diagnosed between
January 2003 and October 2004. Of these, 20 were
newly diagnosed and five were in relapse. Follow-
ing diagnosis, patients began the treatment protocol 
recommended by the Taiwan Pediatric Oncology
Group (TPOG). Information about the subjects, in-
cluding age, gender, WBC count, and central nervous
system (CNS) status, is summarized in Table 1.
After the diagnosis or onset of relapse of ALL and
prior to the initiation of treatment, bone marrow and
peripheral blood samples were collected. Bone marrow
or peripheral blood samples were also collected from
15 subjects 14 days after induction therapy, at the
completion of induction or commencement of consol-
idation therapy, and at commencement of maintenance
therapy. A total of 46 bone marrow samples and 37
peripheral blood samples were obtained.
RT-PCR
RNA was extracted from bone marrow and peripheral
blood samples and cDNA was synthesized. The target
genes were amplified using the cDNA as a template
and the synthetic, two-fragment specific primers. The
PCR primer sequences were based on those used by
van Dongen and colleagues [10], as detailed below:
TEL-A, 5-CCCTCTGATCCTGAAC-3 (anti-sense),
AML1-B, 5-AACGCCTCGCTCATCTTGC-3 (sense),
TEL-C, 5-AAGCCCATCAACCTCTCTCATC-3 (anti-
sense), and AML1-D, 5-TGGAAGGCGGCGTGAA-
GC-3 (sense). Primers A and B were used in the first
round of a nested PCR; then, primers C and D were
used in the second round. Electrophoresis was used
to determine the sizes of the final products. The PCR
products from the first and second rounds of PCR were
181 and 142 bps, respectively, and the REH-cell line
was used as a positive control.
The cDNA prepared from reverse transcription
was blotted on a nylon membrane, allowed to dry,
and secured with XL-1000 CrossLinker (Spectronics,
Westbury, NY, USA). A probe was prepared by PCR
amplification of the REH cell cDNA with the primers
TEL-C and AML1-D. The PCR products were subse-
quently verified by electrophoretic analysis, purified,
and labeled with DIG by DIG High Prime (Roche
Applied Science, Indianapolis, IN, USA) at 37°C for 2
hours. The membrane was then hybridized with DIG-
labeled probes for 12–16 hours at 42°C. Following post-
hybridization washing and blocking, the anti-DIG AP
conjugate was added, and the mixture was washed
again. NBT/BCIP solution was then added for staining.
The β-actin housekeeping gene was amplified with
the primers 5-GACATCCGCAAAGACCTGTA-3 and
5-CAGGAGGAGCAATGATCTTG-3.
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TEL/AML1 and β-actin blotting analyses were car-
ried out for each sample for comparison of the chromo-
genic reactions between the two variables. The results
are presented as the ratio of TEL/AML1 to β-actin.
RESULTS
The results of the bone marrow and peripheral blood
examinations of all 25 study subjects prior to the start
of chemotherapy are summarized in Table 2. Eight
(32%) of them had detectable TEL-AML1 fusion tran-
scripts, including six (30%) of the 20 newly diag-
nosed cases and two (40%) of the five relapsed cases.
Relationship between fusion genes and 
ALL immunophenotypes
Table 3 shows the immunophenotypes of the ALL
patients in this study. The pre-B type was the most
common in the newly diagnosed patients (six patients),
followed by precursor B (five cases), and early pre-B
(four cases) types. The other cases included one with
progenitor B, two with early pre-B with myeloid co-
expression, and two with T cell immunophenotypes.
Of the relapsed cases, two were precursor B type, two
had early pre-B type, and one was the early pre-B type
with myeloid coexpression.
The immunophenotypes of ALL patients with
TEL-AML1 fusion transcripts were precursor B, early
Table 1. Clinical information and gene analysis results for the study subjects
Case Age (yr) Sex WBC
CNS 
Diagnosis
Immunologic 
TEL/AML1 Protocols Outcome 
status markers
1 5.2 M 3.7 I ALL Pre-B − ALL SRA CR
2 6.6 M 3.3 I ALL B precursor + ALL SRB CR
with myeloid
3 5.0 M 3.4 I ALL B precursor + ALL SRA CR
4 6.3 F 8.1 I ALL, B precursor + ALL VHR CR
relapse
5 3.6 F 2.6 I ALL Early pre-B − ALL SRB CR
6 16.8 F 115.4 I ALL Progenitor B − ALL VHR Died
7 15.0 M 24.1 I ALL, Mixed type − ALL VHR 3rd
relapse relapse
8 5.7 F 35.92 I ALL Pre-B − ALL SRB CR
9 8.3 M 288.5 I ALL T cell − ALL VHR CR
10 6.9 M 3.3 I ALL B precursor − ALL SRB CR
11 0.6 M 37.7 I ALL B precursor + ALL VHR CR
12 3.6 M 2.7 I ALL Early pre-B − ALL SRB CR
13 0.2 M 93.1 II ALL Pre-B + ALL VHR CR
14 13.2 M 9.7 I ALL, Early pre-B − ALL VHR Died
relapse
15 4.3 M 9.9 I ALL, Early pre-B + ALL VHR CR
relapse
16 4.3 M 2.1 I ALL Early pre-B + ALL SRA CR
17 8.7 M 40.7 I ALL Early pre-B + ALL HR Died
18 3.7 F 16.6 I ALL B precursor − ALL SRB CR
19 4.42 F 10.6 I ALL Pre-B − ALL SRB CR
20 12.2 F 35.1 I ALL Early pre-B − ALL HR CR
with myeloid
21 3.2 F 31.5 I ALL B precursor − ALL SRB CR
22 10.1 M 1.43 I ALL, B precursor − ALL VHR Died
relapse
23 16.5 M 42.6 I ALL Pre-B − ALL HR CR
24 16.5 M 166.3 I ALL T cell − ALL VHR CR
25 17.0 M 6.1 I ALL Pre-B − ALL HR CR
M = male; F = female; WBC = white blood cell count (×103/μL); CNS I = CSF < 5 WBC/μL without blasts; CNS II = CSF < 5 WBC/μL
with blasts; ICH = intracranial hemorrhage; ALL = acute lymphoblastic leukemia; AML = acute myelogenous leukemia; ALL
SRA = TPOG ALL 2002 SRA; ALL SRB = TPOG ALL 2002 SRB; ALL HR = TPOG ALL 2002 HR; ALL VHR = TPOG ALL 2002 VHR;
CR = complete remission; ND = not done.
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pre-B, and pre-B types. No TEL-AML1 fusion tran-
scripts were detected in any T- or B-cell ALL patients
with myeloid coexpression. The occurrence of the
fusion gene was the highest in the precursor B type
patients, with four (57%) of the seven patients exp-
ressing the gene. In contrast, the fusion gene was
identified in only one (16.6%) of the six pre-B ALL
patients.
Relationship between fusion genes and
other clinical findings
Age is an important prognostic factor for ALL. Past
research has shown that better prognosis is associ-
ated with ages between 1 and 10, while those aged
younger than 1 or older than 10 years have poorer
prognosis. The majority (15) of the study subjects was
aged between 1 and 10 years; two were less than 1 year
old; and eight were over 10 years old. Most (6/8) of the
cases with the TEL/AML1 fusion gene were also
between the ages of 1 and 10 years.
The patients were grouped according to their WBC
count at the time of diagnosis: the groups were < 50 ×
103/μL (21 patients), 50–100×103/μL (one patient), and
> 100 × 103/μL (three patients). Among the 21 patients
with WBC count <50×103/μL, seven were TEL/AML1
positive. The patient with WBC count between 50 and
100 × 103/μL was also TEL/AML1 positive. However,
none of the three patients whose WBC counts were
greater than 100 × 103/μL was TEL/AML1 positive.
Only one subject in this study had CNS II status
(cerebrospinal fluid [CSF] cell count <5 WBC/μL with
blasts), and this particular patient was TEL/AML1
positive. All of the other subjects had CNS I status
(CSF < 5 WBC/μL without blasts) and no subject had
Table 2. Gene analyses and associations with age, white blood cell (WBC) count, central nervous system (CNS) status,
gender, and chromosome study
TEL-AML1
Total
Positive (n = 8) Negative (n = 17)
Age (yr)
< 1 2 0 2
1–10 6 9 15
> 10 0 8 8
WBC count (× 103/μL)
< 50 7 14 21
50–100 1 0 1
> 100 0 3 3
CNS status
I 7 17 24
II 1 0 1
III 0 0 0
Gender
Male 7 10 17
Female 1 7 8
Chromosome study
Normal karyotype 6 15 21
Abnormal 2 2 4
Table 3. Gene analysis and comparison with different
immunophenotypes
Patients, n
TEL-AML1 
positive, n (%)
Fresh cases 20 6 (30)
Progenitor B 1 0
Precursor B 5 3
Early pre-B 4 2
Pre-B 6 1
T cell 2 0
B cell with myeloid 2 0
Relapsed cases 5 2 (40)
Precursor B 2 1
Early pre-B 2 1
B cell with myeloid 1 0
Total 25 8 (32)
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CNS III status (cell count > 5 WBC/μL with blasts) or
signs of CNS leukemia at the time of diagnosis.
Seventeen of the 25 subjects (68%) recruited in this
study were male. TEL/AML1 was positive in seven of
them, but in only one of the eight females in the study.
All of the subjects underwent a chromosome study
at the time of diagnosis. Most showed a normal kary-
otype, but the following abnormalities were found 
in four subjects: hyperploidy (> 50 chromosomes);
47XY,+8; 45XY,t(5;15)(p15;q13),−17; and the Phila-
delphia chromosome [46XX,t(9;22)(q34;q11)]. The
t(12;21)(p13;q22) abnormality was not detected in any
patient.
Treatment response
The 20 newly diagnosed ALL patients underwent
treatment with the protocol recommended by the
TPOG. The TPOG ALL 2002 (Standard Risk) was
started in 11 patients, the TPOG ALL 2002 (High Risk)
in four, and the TPOG ALL 2002 (Very High Risk) in
five. With one exception (a patient who tested negative
for TEL-AML1), all of the patients achieved complete
remission by the end of induction therapy. One TEL-
AML1 positive patient relapsed during consolidation
therapy and subsequently died from advanced dis-
ease. To date, all of the other 18 subjects remain in
remission, with the longest follow-up period being 
2 years.
Of the five relapsed cases, two were TEL-AML1
positive. Following completion of the TPOG ALL 2002
Very High Risk treatment regimen, they both achieved
and remained in remission. The other three relapsed
patients did not achieve remission. Two died from pro-
gressive disease and one continues to receive treatment.
Quantitative analysis of fusion genes at
different disease stages
The study of bone marrow and peripheral blood sam-
ples commenced after the initiation of treatment in
TEL-AML1 positive ALL patients. Of the eight TEL-
AML1 positive ALL patients, samples were only
available from two at the time of diagnosis, while
samples collected after the start of treatment were
available from the other six patients. A total of 11 bone
marrow samples and nine peripheral blood samples
were examined by blotting analysis, the results of
which are shown in Table 4. Only one (Case 17) of the
eight cases relapsed during consolidation therapy. In
the other seven cases, the proportion of lymphoblast
cells fell from 95% at diagnosis to less than 2% at the
completion of induction therapy, and continued to
remain in remission.
Table 4. Quantitative analysis of fusion gene at different stages of illness in six TEL-AML1-positive individuals
Case Sample Ratio (TEL-AML1/β-actin) Sample collection time
2 BM1 1.35 Before C/T
BM2 0.36 Induction day 14
BM3 0.02 Induction day 36
3 BM 2.18 Before C/T
4 BM1 0.43 Before C/T
BM2 0.08 3 mo after C/T
11 PB1 2.73 Before C/T
PB2 0.10 After 1st phase of induction (2 mo after C/T)
PB3 0 Before consolidation (5 mo after C/T)
13 PB1 0 Before C/T
PB2 1.79 Induction day 36
PB3 0 After consolidation (6 mo later)
15 PB 0.85 Before C/T
16 PB1 0.75 Before C/T
BM2 0.64 On maintenance (6 mo later)
PB2 0.58 On maintenance (6 mo later)
17 BM1 0 Before C/T
BM2 0.95 Relapse (7 mo after initial diagnosis)
BM3 1.40 8.5 mo after initial diagnosis
BM4 0.54 9.5 mo after initial diagnosis
BM = bone marrow; PB = peripheral blood; C/T = chemotherapy.
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It was observed that the expression of TEL-AML1
fusion transcripts dramatically dropped in Cases 2, 4
and 11, and a similar trend (but with a smaller ampli-
tude) was also seen in Case 16. The bone marrow
samples of Cases 2 and 4 and the peripheral blood
sample of Case 11 showed a similar degree of reduced
gene expression. Unfortunately, we were not able to
collect both samples at various time points in the same
patient. Otherwise, the analysis of peripheral blood
could have been more firmly evaluated.
DISCUSSION
The TEL/AML1 fusion gene is thought to be the
most common leukemia-specific fusion gene in chil-
dren with ALL as it is present in 20–25% of patients.
Most of these patients are aged between 1 and 10 years,
have a WBC count <50,000/μL, and have the B-lineage
immunophenotype [10,18]. Our findings are consis-
tent with those reported in previous literature: among
the TEL-AML1 fusion gene-positive patients, 88%
(7/8) had WBC count < 50,000/μL, all (8/8) were of
B-lineage immunophenotype, and most (75%, 6/8)
were between 1 and 10 years of age.
In four of the six patients with an available series
of tissue samples, the expression level of the TEL-
AML1 fusion transcript matched the clinical course
of the illness. The rationale behind looking for the
TEL-AML1 fusion transcript as a means to detect
minimal residual disease has been supported by
many researchers. However, accurate quantization 
of the gene has more important clinical implica-
tions. For instance, de Haas and colleagues [19] and
Pallisgaard and colleagues [20] provided evidence
that the quantization of TEL-AML1 by real-time 
PCR correlated with clinical findings. Although our
study did not employ real-time quantitative PCR,
our results were similar to the findings of these two
studies.
The limitation of this study was its small sample
size. Thus, the correlation between TEL-AML1 fusion
transcript expression level and disease relapse could
not be reliably established from the single relapsed
patient in the study. More cases will be required 
for future research to confirm the efficacy of our
quantization method using TEL-AML1 fusion tran-
scripts as the target gene for the estimation of disease
progression.
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